The California Institute of Technology (Caltech) has filed a lawsuit against Bio-Rad Laboratories, alleging that the diagnostics company infringed on its patented DNA analysis technology. The legal complaint was submitted to the U.S. District Court for the Northern District of California.
Court filings state that Caltech claims Bio-Rad incorporated its proprietary multiplexing technology into two diagnostic platforms the QX600 and QX ONE without obtaining permission. This sophisticated technique enables the detection of multiple genetic markers within a single sample by using colored fluorescent tags, a method extensively utilized in genomic and clinical diagnostics.
Caltech is pursuing monetary compensation along with a court injunction to prevent Bio-Rad from continuing to use and market this technology. The university asserts that the patented innovation was designed to improve diagnostic accuracy and efficiency across various medical fields, including cancer research, infectious diseases, and gene therapy.
The contested technology is central to multiplex diagnostics, which plays an increasingly vital role in providing fast and precise genetic analyses. Caltech argues that unauthorized use of its innovations diminishes years of research efforts and investment in molecular testing.
Bio-Rad, based in Hercules, California, has not yet issued a public response to the allegations. However, the company is already engaged in a separate but related legal dispute with ChromaCode, a molecular diagnostics startup founded by Caltech researchers, which also involves claims related to misuse of advanced multiplexing technologies.
In the current lawsuit, Caltech alleges that Bio-Rad knowingly exploited the patented technology in products marketed for clinical research, environmental monitoring, and industrial diagnostic purposes actions the university describes as intentional breaches of intellectual property rights.
The resolution of this case could have significant consequences for the diagnostics industry, where intellectual property rights over multiplex assays and droplet-based technologies are highly contested. As personalized medicine advances, safeguarding innovations in molecular diagnostics remains a critical focus for both academic institutions and commercial developers.
